SCIENTIFIC ADVISORY
Prof. Roger D. Kornberg
Advisory
Professor Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University, Stanford, California. He has been a member of the faculty of Stanford University since 1972. Prior to that, he was a professor at Harvard Medical School. Professor Kornberg is a renowned biochemist, and in 2006, he was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of eukaryotic transcription, the process by which DNA is copied to RNA.
Professor Kornberg joined Omnix at inception. He has served as a director of Protalix since 2008; he has served as a director of OphthaliX Inc. since 2012; and of Biozone Pharmaceuticals, Inc. since 2014. Professor Kornberg served as a director of Teva Pharmaceuticals from 2007 through 2013, and he also serves as the Chief Scientist and a director of Biozone Pharmaceuticals.
Professor Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopold Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. He received his B.Sc. in Chemistry from Harvard University and his PhD in Chemistry from Stanford University. He holds honorary degrees from universities in Europe and Israel, including the Hebrew University in Jerusalem, where he currently is a visiting professor.
As Chairman of the BoD, Dr. Schuh is the architect of Omnix execution and milestone-driven strategy to achieve the company’s future goals.
Dr. Lynn L. Silver
Microbiology Development Advisory
Former Merck executive, Dr. Lynn Silver, has more than 30 years of experience in the antibacterial discovery field. Dr. Silver, a highly appreciated KOL, provides insight and advice to the research community on global advisory panels, international collaborations for addressing antibiotic resistance issues and has published numerous highly-cited reviews.
At Omnix, Dr. Silver advises as per all aspects of Microbiology and project progress. Moreover, Dr. Silver takes active part in the Scientific Selection Board for Novo Holdings (Repair Fund); in the Scientific Advisory Board, Combating Antibacterial Resistant Bacteria for CARB-X; as an Expert Advisor, Global Antibiotic Research and Development Partnership (GARD-P); and is positioned as the Discovery Expert Advisor with the Pew Charitable Trust Shared Platform for Antibiotic Research and Knowledge (SPARK). Dr. Silver is also a Reviewer on NIH Study Sections Editorial Board, Antimicrobial Agents and Chemotherapy.
Prof. Yehuda Carmeli, MD
Medical Advisory
Prof. Carmeli, a world leader in the area of antimicrobial resistance, is the Head of the Israeli National Center for Antibiotic Resistance, Head of Epidemiology and Preventive Medicine at the Tel Aviv Medical Center, and a Professor of Medicine at the Tel Aviv University, Israel. He received his MD degree from Ben Gurion University, Israel and his MPH degree at Harvard School of Public Health. Following his residency at Hadassah Medical Center, Hebrew University, he served as a fellow in Medicine at Massachusetts General Hospital, Boston. Professor Carmeli completed his fellowship in Infectious Diseases at Beth Israel Deaconess Medical Center, Boston, MA.
Currently, Prof. Carmeli is also on the research staff at the Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. His primary research interest is the epidemiology of resistance to antibiotics. He is the co-author of over 200 scientific publications, the recipient of multiple research grants and awards, and a member of the editorial board of major journals in the fields of infectious diseases and antibiotic research. Prof Carmeli has been studying A. baumannii and performing clinical studies in the anti-infective area in EU/US for more than 20 years. He brings to Omnix his vast experience and network that have been constructed over time, and he is advising and assisting in building the clinical strategy throughout all the medical and clinical aspects of the Omnix programs.
Dr. Michael Mizhiritzkii
CMC Advisory
Dr. Michael Mizhiritzkii is an innovative specialist in medicinal-chemistry with a strong record of developing quality drug candidates and lead compounds. He has led or collaborated on projects through all phases of drug discovery and specializes in guidance on tactics of individual projects from target selection and hit identification, through hit-to-lead, lead optimization and early clinical studies. Dr. Mizhiritzkii holds a PhD in organic chemistry from Leningrad Technological Institute and has worked in the biotech industry for over two decades.
Since 2007, Dr. Mizhiritzkii has worked as an independent consultant in organic, bio-organic and medicinal-chemistry and CMC advisor. He has collaborated on over 100 projects in the pharma, agrochemical, green chemistry and biotechnology sectors, with companies such as Heparx, Lutris Pharma, Reltar Therapeutics, M.G. Therapeutics, Galmed, Paz Oil Company, Makhteshim Chemical Works, Agan Chemical Manufactures, Perrigo, Chemagis, IMI TAMI Institute for Research and Development Ltd, MIGAL – Galilee Technology Center, Haifa Chemicals as well as several start-ups.
Dr. Mizhiritzkii joined Omnix in 2018 and advises on solutions and strategy for multi-step organic synthesis in light of economical parameters. He is critical to the intermediate production and custom synthesis of peptide API, as well as to process development and production from laboratory to industrial scale.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).